Galmed Pharmaceuticals (NASDAQ:GLMD) announced its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.20) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.24) by $0.04, Morningstar.com reports.
Shares of Galmed Pharmaceuticals stock traded up $0.06 on Tuesday, reaching $4.95. 3,920 shares of the company were exchanged, compared to its average volume of 48,351. Galmed Pharmaceuticals has a 1-year low of $4.50 and a 1-year high of $14.65. The company has a market capitalization of $105.21 million, a P/E ratio of -9.17 and a beta of 2.61. The company has a debt-to-equity ratio of 0.01, a quick ratio of 36.11 and a current ratio of 36.11. The stock’s 50 day moving average is $6.47.
GLMD has been the subject of a number of analyst reports. Maxim Group reissued a “buy” rating and set a $20.00 price objective on shares of Galmed Pharmaceuticals in a research report on Tuesday. HC Wainwright reissued a “buy” rating on shares of Galmed Pharmaceuticals in a research report on Tuesday. ValuEngine raised Galmed Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, June 28th. Finally, Laidlaw initiated coverage on Galmed Pharmaceuticals in a research report on Monday, July 22nd. They set a “buy” rating and a $25.00 price objective for the company. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $28.17.
Galmed Pharmaceuticals Company Profile
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is completed ARREST Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis.
Read More: What is a price target?
Receive News & Ratings for Galmed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.